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ABSTRACT
Background: Preconceptional maternal small-quantity lipid-based nutrient supplementation (SQLNS) improved
intrauterine linear growth in low-resource countries as demonstrated by the Women First Preconception Maternal
Nutrition Trial (WF). Fetal growth is dependent on nutrient availability and regulated by insulin-like growth factor 1 (IGF-1)
through changes in placental transfer capacity, mediated by the mechanistic target of rapamycin (mTOR) pathway.
Objectives: Our objective was to evaluate the role of placental mTOR and IGF-1 signaling on fetal growth in women
from 2 low-resource countries with high rates of stunting after they received preconceptional SQLNS.
Methods: We studied 48 women from preconception through delivery who were from Guatemala and Pakistan and
received SQLNS or not, as part of the WF study. Placental samples were obtained at delivery (control, n = 24; SQLNS,
n = 24). Placental protein or mRNA expression of eukaryotic translation initiation factor binding protein-1 (4E-BP1),
ribosomal protein S6 (rpS6), AMP-activated protein kinase α (AMPKA), IGF-1, insulin-like growth factor receptor (IGF1R), and pregnancy associated plasma protein (PAPP)-A, and DNA methylation of the IGF1 promoter were determined.
Maternal serum IGF-1, insulin-like growth factor binding protein (IGFBP)-3, IGFBP-4, IGFBP-5, PAPP-A, PAPP-A2, and
zinc were measured.
Results: Mean ± SEM maternal prepregnancy BMI differed between participants in Guatemala (26.5 ± 1.3) and Pakistan
(19.8 ± 0.7) (P < 0.001). In Pakistani participants, SQLNS increased the placental rpS6(T37/46):rpS6 ratio (1.5-fold)
and decreased the AMPKA(T172):AMPKA ratio. Placental IGF1 mRNA expression was positively correlated with birth
length and birth weight z-scores. Placental PAPP-A (30-fold) and maternal serum zinc (1.2-fold) increased with SQLNS.
In Guatemalan participants SQLNS did not influence placental mTOR signaling. Placental IGF-1R protein expression
was positively associated with birth length and birth weight z-scores. SQLNS increased placental PAPP-A (40-fold) and
maternal serum IGFBP-4 (1.6-fold).
Conclusions: In Pakistani pregnant women with poor nutritional status, preconceptional SQLNS activated placental
mTOR and IGF-1 signaling and was associated with improved fetal growth. In contrast, in Guatemalan women SQLNS
did not activate placental nutrient-sensing pathways. In populations experiencing childhood stunting, preconceptional
SQLNS improves placental function and fetal growth only in the context of poor maternal nutrition. This trial was
registered at clinicaltrials.gov as NCT01883193. J Nutr 2020;00:1–14.
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Preconceptional Lipid-Based Nutrient
Supplementation in 2 Low-Resource Countries
Results in Distinctly Different IGF-1/mTOR
Placental Responses

Introduction
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Methods
Study design
This study was part of a randomized controlled trial registered as
Women First (NCT01883193), which was designed to determine the
optimal timing of maternal nutrition supplementation to improve
fetal linear growth. The trial was conducted in rural and semirural
locations in Guatemala (Chimaltenango Department) and Pakistan
(Thatta, Sindh Province) where stunting rates are high (27).

Participants
The present study focused on a subcohort of Guatemalan and Pakistani
women from whom ∼50 placentas were collected at each site. Women
signed informed consent for participation, which was approved by the
Colorado Multiple Institutional Review Board, University of Colorado,
and by the local and/or national ethics committees. Women were
randomly assigned to a daily small-quantity lipid-based micronutrient
supplementation (SQLNS, Nutriset) starting ≥3 mo before conception
and continuing until delivery (preconceptional SQLNS, arm 1) or no
nutritional supplementation at all (control group, arm 3). SQLNS is a
commercially available supplement developed for low-resource settings
that has been used to enrich the diets of pregnant women (28, 29).
The composition has been described in detail in the published WF
protocol (27). Women taking SQLNS were also provided with an
additional daily lipid-based protein-energy supplement (no additional
micronutrients) under 2 conditions: BMI (in kg/m2 ) <20 at any time
while receiving SQLNS or inadequate gestational weight gain based
on the Institute of Medicine guidelines (30). This second supplement
provided 300 kcal and 12 g protein; recipients were encouraged to
consume ≥50% without leading to reduced intake of their habitual
diet. Women in the control group (arm 3) received no nutritional
supplements. Compliance was documented by biweekly collection
of empty sachets, self-reported consumption, and random audits by
on-site personnel. Compliance for this study was calculated by the
total number of sachets fully eaten divided by the total number of
days between starting supplementation and delivery, reported as a
percentage.
Participants whose placenta was collected at delivery from each site
(n = 50, convenience sample) were categorized into quartiles according
to their newborns’ birth length. A total of 12 participants from the
first and fourth quartiles per treatment arm and site (n = 24/site)
were included in the study. Gestational age was confirmed by firsttrimester ultrasound crown–rump length and only pregnancies with
term deliveries (>37 weeks of gestation) were included. Newborn
length and weight were obtained within 48 h of birth by trained study
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Linear growth is an indicator of a child’s well-being and
is an accurate marker of population inequalities in human
development (1). Low birth weight (LBW) is common in undernourished populations in low- and middle-income countries
(LMICs) and has been associated with childhood stunting.
Stunting has been identified as a major global public health
problem with short- and long-term health consequences, such
as deficits in cognitive function and decreased adult economic
productivity (2). Overall, it has been estimated that 20% of
childhood stunting could have its origins in the fetal period
(3). The pathogenesis underlying linear growth failure is not
well established, but it likely begins in utero and continues into
postnatal life (4, 5).
Short maternal stature, suboptimal maternal nutrition, and
poor weight gain during pregnancy are major factors associated
with LBW (2, 6). Human and animal studies have suggested a
beneficial effect on birth outcomes when maternal underweight
and micronutrient deficiencies are improved before conception
(7, 8). Recently, the Women First Preconception Maternal
Nutrition Trial (WF) demonstrated that poor fetal growth
in low-resource countries, including linear growth, can be
improved with maternal nutritional supplementation initiated
before conception or late in the first trimester (9).
Nutrient transfer across the placenta is critically important
for fetal growth and programs the fetus for diseases later in life
(10). The placenta is known to adapt its structure and function
in response to maternal fitness, thereby affecting fetal growth
(11, 12). We have previously demonstrated that the placenta acts
as a nutrient sensor, highlighting the role of mechanistic target of
rapamycin (mTOR), which regulates energy-requiring processes
including growth, nutrient transport, and protein synthesis
(13).
In humans, maternal concentration of insulin-like growth
factor-1 (IGF-1) is positively correlated with birth weight
(14). IGF-1, insulin-like growth factor receptor (IGF-1R), and
IGF binding proteins (IGFBPs) are expressed in the placenta.
In vivo and in vitro studies have shown endocrine and
autocrine/paracrine actions of IGF-1 in regulating fetal growth
and placental transport capacity (15, 16).
IGF-1 activity is regulated by pregnancy-associated plasma
protein (PAPP)-A and PAPP-A2, zinc binding metalloproteinases (17). Lack of PAPP-A activity increases IGFBP-4
concentrations, resulting in an ∼40% decrease in fetal growth
in mice (18, 19) and intrauterine growth restriction in humans

(20). Prenatal maternal zinc supplementation is associated with
greater fetal weight in a low-resource population (21) and
zinc supplementation in zinc-deficient short children increased
plasma IGF-1 (22, 23).
Alterations in DNA methylation in the promoter of the
IGF1 gene have been associated with fetal growth. Placentas
from growth-restricted newborns have higher levels of DNA
methylation in the promoter regions of the IGF1 gene than
those from newborns with normal growth (24). High levels
of DNA methylation of the P2 promoter of the IGF1 gene
in mononuclear blood cells were observed in children with
idiopathic short stature (25) and negatively correlated with
serum IGF-1 concentration and child height (26).
Based on the divergent impact of preconceptional smallquantity lipid-based nutrient supplementation (SQLNS) on
birth length in Guatemala and Pakistan in the WF trial, we
sought to determine the effect of maternal preconceptional
SQLNS on placental mTOR and IGF-1 signaling and their
association with fetal growth in these 2 low-resource countries
where stunting is prevalent.

TABLE 1 Baseline characteristics of study participants, presented by site and treatment arm1
Guatemala study site
Control
(arm 3)

1

Preconceptional
SQLNS (arm 1)

25.2 ± 1.50
1.66 ± 0.33
1
26.5 ± 1.31a
0
6
4
2
147 ± 1.03
57.5 ± 3.26a
38.9 ± 0.35
5.41 ± 1.19

25.0 ± 1.18
1.33 ± 0.25
2
26.3 ± 1.33a
0
5
4
3
147 ± 1.36
57.0 ± 2.83a
39.4 ± 0.27
5.33 ± 1.38

9
3
—
—
2.83
48.0
− 0.79
− 1.01

±
±
±
±

7
5
79.0 ± 4.50
2/12
0.11
0.59
0.33
0.24

2.98
48.0
− 0.52
− 0.68

6
6
162 ± 10.3a

±
±
±
±

0.11
0.69
0.39
0.29

6
6
176 ± 9.70a

Control
(arm 3)
24.0 ± 1.20
1.58 ± 0.54
5
19.8 ± 0.68b
4
7
1
0
152 ± 2.25
46.2 ± 2.22b
39.0 ± 0.32
6.33 ± 1.88
12
0
—
—
2.81
47.2
− 1.05
− 1.05

±
±
±
±

0.12
0.92
0.51
0.25

Preconceptional
SQLNS (arm 1)
24.4 ± 1.13
1.75 ± 0.47
3
19.7 ± 0.70b
5
6
1
0
148 ± 2.03
43.9 ± 1.10b
39.4 ± 0.45
5.66 ± 1.53

P value
NS
NS
NS
<0.001

NS
<0.01
NS
NS

12
0
91.1 ± 2.89
10/12

0.01
<0.0001

±
±
±
±

NS
NS
NS
NS

2.70
48.0
− 0.67
− 1.41

5
7
82.8 ± 14.7b

0.16
0.81
0.50
0.37

5
7
115 ± 5.56c

<0.05

Values are means ± SEMs, n = 12. Labeled means in a row without a common letter differ, P < 0.05. SQLNS, small-quantity lipid-based nutrient supplementation.

personnel. Gestational-age-adjusted length and weight were determined
based on INTERGROWTH-21st fetal growth charts (31).

Tissue collection
Placental dimensions were obtained after delivery by alignment of
the longest axis of the placenta (width) on a grid and recording the
widest point perpendicular to the longest dimension axis (length).
Placental tissue was collected from 4 representative locations (1 cm3
each), washed, and immersed into PBS with protease inhibitors or
RNAlaterTM (Thermo Fisher Scientific). Samples were stored at −80◦ C
until further analysis. Collection time and storage temperature were
recorded until samples were shipped to the University of Colorado,
Denver, USA.

Placental protein expression
Placentas were thawed and homogenized in PBS solution containing
protease inhibitor (1:100; Sigma Aldrich Cat. No. P8340) and
phosphatase inhibitor cocktails 2 and 3 (1:100; Sigma Aldrich Cat. Nos.
P5726, P0044). Equal amounts of total protein (1 μg) from placental
homogenates were used to determine the total and phosphorylated
proteins using the automated capillary electrophoresis Simple Western
system (Protein Simple, Cat. Nos. SM-W004-1, PS-ST01, PN-009050, DM-001). Proteins were separated and probed using primary
antibodies for total AMP-activated protein kinase α (AMPKA),
AMPKA(T172), total ribosomal protein S6 (rpS6), rpS6(S235/236),
total eukaryotic translation initiation factor binding protein-1 (4E-BP1),
4E-BP1(T37/46), IGF-1R, PAPP-A, and zinc influx SLC39A transporter
(SLC39A10). Vinculin or β-actin served as the loading controls
(Supplemental Table 1). Analysis was performed by Compass (Protein
Simple, San Jose, CA, 95134) software (32). For comparison purposes

the mean protein expression of placentas from nonsupplemented
women (control) was assigned a value of 1.0 and used as a reference.

Placental IGF1 mRNA expression
Total placental RNA was extracted using an RNase Mini Plus kit
(Qiagen, Cat. No. 74136) after homogenization of 100 mg placental
tissue in 900 μL TRI Reagent (Life Technologies, Cat. No. 15596-026).
Quantity and quality of total RNA were analyzed using a NanoDrop
2000/2000c spectrophotometer (Thermo Fisher Scientific). Reverse
transcription was performed using 1.0 μg total RNA according to the
manufacturer’s protocol (High-Capacity cDNA Reverse Transcription
Kit with RNase Inhibitor, Applied Biosystems, Cat. No. 4374966).
Expression of the IGF1 gene (Hs01547656_m1) was determined
in placental samples by qRT-PCR using Taqman probes (TaqMan
Gene Expression Assay-Standard Condition, Applied Biosystems, Cat.
No. 4370048) in duplicate and analyzed using the QuantStudio 6
Flex system (Applied Biosystems). Relative expression of the IGF1
gene was normalized to the geometric mean of 18S ribosomal RNA
(RNA18S5, Hs03928985_g1) and 3-monooxygenase/tryptophan 5monooxygenase activation protein ζ (YWHAZ, Hs01122445_g1) using
the CT method. Endogenous reference gene expression was similar
in placentas from control and supplemented women.

Placental DNA methylation
The P2 promoter region of the IGF1 gene was assessed based on
a previous association between higher DNA methylation in this
regulatory element and human early growth (26). We focused on an
area of open chromatin in the P2 promoter, as defined by the presence
of H3K27 acetylation and DNase hypersensitivity (Supplemental Figure
1). The DNA sequence from this region was analyzed using PyroMark
Assay Design Software (Qiagen) and the 2 highest-performing primer
Maternal supplementation and placental function
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Mother
Maternal age, y
Parity
Nulliparity, n
BMI, kg/m2
Underweight, n
Normal, n
Overweight, n
Obese, n
Height, cm
Weight, kg
Gestational age at delivery, wk
Weight gain at 34 wk, kg
Mode of delivery, n
Vaginal
Cesarean
SQLNS compliance, %
Protein supplement frequency, n
Newborn
Birth weight, kg
Birth length, cm
Length-for-gestational-age z-score
Weight-for-gestational-age z-score
Sex, n
Male
Female
Placental area, cm2

Pakistan study site

sets were selected. Bisulfite-converted DNA was PCR amplified with
1 biotinylated PCR primer. A sequencing primer was then added,
which anneals to the single-stranded DNA template. Pyrosequencing
was performed on the PyroMark Q96 MD sequencer (Qiagen) using
reagents and protocols recommended by the manufacturer. Each plate
contained 0%, 50%, and 100% methylated controls. Percentage
methylation was calculated from the peak heights of C and T using the
Pyro Q-CpG software (Qiagen). PCR and sequencing were performed
in duplicate for each sample and mean values were used in the statistical
analysis.

Measurements of maternal serum hormones and zinc
concentrations
Maternal serum concentrations of total IGF-1, IGFBP-3, IGFBP-4,
IGFBP-5, PAPP-A, and PAPP-A2 at 34 weeks of gestation were determined by a solid-phase quantitative sandwich enzyme immunoassay
technique (R&D Systems, Cat. Nos. DG100, DGB300; Ash Labs, Cat.
Nos. AL-128, AL-127, Al-106, AL-109). Samples were run in duplicate.
A pooled serum sample and a commercial quality control sample
(R&D Systems, Cat. No. QC22) were used to evaluate reproducibility.
Concentrations (ng/mL or mIU/mL) were calculated using a known
standard curve run on each plate.
Maternal serum zinc concentration at 34 weeks of gestation
was determined by inductively coupled plasma MS using Agilent
Technologies model 7700× (Agilent Technologies). Precautions were
taken to avoid zinc contamination during the collection, handling, and
4
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storage of specimens. Concentrations (μg/dL) were calculated based
on a commercial standard solution used to generate a standard curve
(Sigma Aldrich TraceCERT, Cat. No. 75594).

Data presentation and statistical analysis
Participants’ baseline characteristics were compared using 1-factor
ANOVA and Tukey’s multiple comparisons test. Comparisons between
the maternal preconceptional SQLNS and control groups were evaluated by Student’s unpaired t test. The data complied with homoscedastic
or normality assumptions. In order to further explore underlying
factors determining fetal growth trajectories in these 2 populations,
control and preconceptional SQLNS data were pooled and Pearson’s
correlation unadjusted models were used to examine associations
between placental protein expression, maternal serum proteins, and
fetal growth parameters. A P value < 0.05 and α = 0.05 were considered
statistically significant. Data are presented as mean ± SEM. Statistical
analysis was performed using Prism 8.0 software (GraphPad Software,
Inc.).

Results
Participant characteristics
Selected clinical characteristics are presented by site and
stratified by treatment arm (Table 1). There were no
statistical differences between women in the 2 treatment
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FIGURE 1 Effect of preconceptional SQLNS on placental AMPK and mechanistic target of rapamycin signaling in Pakistan (A–C) and Guatemala
(D–F). The histogram shows the relative protein expression of the (A, D) AMPKA (T172):total AMPKA ratio, (B, E) rpS6 (S235/236):total rpS6 ratio,
and (C, F) 4E-BP1 (T37/46):4E-BP1 ratio. Representative individual Protein Simple Western Blot capillaries are shown for total and phosphorylated
proteins and vinculin as loading control. Data are presented as mean ± SEM, n = 12. ∗,∗∗ Different from control: ∗ P < 0.05, ∗∗ P < 0.005
(Student’s unpaired t test). AMPKA, AMP-activated protein kinase α; rpS6, ribosomal protein S6; SQLNS, small-quantity lipid-based nutrient
supplementation; 4E-BP1, eukaryotic translation initiation factor binding protein-1.

arms for maternal age, height, and weight gain at 34 weeks
of gestation or parity. Participants from Guatemala started
pregnancy with a significantly higher preconceptional BMI
than Pakistani participants. Within each study site preconceptional BMIs between each treatment arm were not
different.
Guatemalan participants reported 70% compliance in
consuming SQLNS (Supplement 1) from before conception until
delivery, which was significantly lower than Pakistani participants, who reported 91% compliance. Supplement compliance
was not identified as a factor in fetal growth outcomes (9). All
Pakistani participants in this subcohort received Supplement
2 and reported high compliance (>90%). Only 2 Guatemalan
participants received Supplement 2.
In this cohort of participants, there were no significant
differences between sites and treatment arms in birth weight,
birth length, length-for-gestational-age z-scores, or weight-forgestational-age z-scores. Placental area was not statistically
different between treatment arms in Guatemalan participants.
Overall, Pakistani participants had significantly smaller placental areas than Guatemalan participants; however, Pakistani
mothers who received preconceptional SQLNS had a significantly larger (+1.4-fold, P = 0.03) placental area than the
control arm and placental area was correlated with length-forage z-score (P = 0.05, r = 0.39).
Effect of preconceptional SQLNS on the placental
mTOR signaling pathway
In Pakistani participants, in terms of protein expression,
preconceptional
SQLNS
decreased
the
placental
AMPKA(T172):AMPKA ratio (Figure 1A) (P = 0.001)
and increased the placental rpS6(S235/236):rpS6 ratio
(Figure 1B) (+1.5-fold, P = 0.03) and 4E-BP1(T37/46):

4E-BP1 ratio (Figure 1C) (+1.6-fold, P = 0.09) as compared
with control participants. Collectively these results suggest an
inhibition of AMPK signaling and an activation of mTOR
signaling in women receiving SQLNS. In contrast, in placentas
from Guatemalan participants preconceptional SQLNS had no
effect on AMPK or mTOR signaling activity, as evidenced by
no difference in the placental AMPKA(T172):AMPKA ratio
(Figure 1D), rpS6(S235/236):rpS6 ratio (Figure 1E), or 4EBP1(T37/46):4E-BP1 ratio (Figure 1F) between the 2 treatment
arms. We found no significant correlations between placental
mTOR signaling and length-for-age z-score in either study
site [AMPKA(T172):AMPKA ratio: Guatemala P = 0.49, r =
−0.002; Pakistan P = 0.46, r = −0.02; rpS6(S235/236):rpS6
ratio: Guatemala P = 0.22, r = 0.26; Pakistan P = 0.40,
r = 0.06; 4E-BP1(T37/46):4E-BP1 ratio: Guatemala P = 0.97,
r = 0.008; Pakistan P = 0.84, r = 0.04].
Effect of preconceptional SQLNS on placental
expression of IGF1 and maternal serum concentration
of IGF-1 and its association with fetal growth
Preconceptional SQLNS did not affect the relative mRNA
expression of IGF1 in placental tissues for either site
(Figure 2A, E). In Pakistani participants, we found a borderline
significant positive correlation between maternal serum IGF1 concentrations (P = 0.06, r = 0.12), placental mRNA
expression of IGF1 (P = 0.05, r = 0.42), and birth length z-score
(Figure 2B, C), but no association between placental expression
of IGF-1R and fetal linear growth (Figure 2D). Conversely,
in Guatemalan participants there was no association between
maternal serum IGF-1 concentration or placental mRNA IGF1
expression and birth length (Figure 2F, G) but the protein
expression of placental IGF-1R was positively correlated
(P = 0.0007, r = 0.68) with birth length z-score (Figure 2H).
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FIGURE 2 Effect of preconceptional SQLNS on, and the association of the IGF-1 axis with, birth length in Pakistani (A–D) and Guatemalan
(E–H) study sites. (A, E) The histogram shows relative placental IGF1 mRNA expression by treatment arm (control, arm 3; SQLNS, arm 1) and
site. Data are presented as mean ± SEM, n = 12. Pearson’s correlation of (B, n = 19; F, n = 20) maternal serum concentration of IGF-1, (C,
n = 19; G, n = 22) relative placental IGF1 mRNA expression, and (D, n = 19; H, n = 22) placental protein expression of IGF-1R with birth length
z-score. AU, arbitrary units; IGF-1, insulin-like growth factor-1; IGF-1R, insulin-like growth factor receptor; SQLNS, small-quantity lipid-based
nutrient supplementation.

In a similar pattern in Pakistani participants, we found a
nonsignificant positive association of maternal serum IGF-1
concentration (P = 0.19, r = 0.21) and a positive significant
correlation of placental mRNA expression of IGF1 (P < 0.01,
r = 0.52) with birth weight z-score (Supplemental Figure
2A, B). In Guatemalan participants we found a significant
correlation between placental protein expression of IGF-1R
and birth weight z-score (P < 0.01, r = 0.68) (Supplemental
Figure 2F). In Guatemalan participants, no association was
found between maternal serum IGF-1 concentrations, placental
mRNA expression of IGF1, and birth weight (Supplemental
Figure 2D, E). In Pakistani participants, placental protein
expression of IGF-1R was not correlated with birth weight
z-score (Supplemental Figure 2C) and placental area was
positively correlated with birth length and birth weight zscores and placental mRNA expression of IGF1 (Supplemental Figure 3A, B, D). In contrast, these associations
were not observed in the Guatemalan cohort (Supplemental
Figure 3E–H).

Placental DNA methylation of the IGF1 gene promoter
and its association with fetal growth
Overall, no significant differences in placental DNA methylation, reported as percentage methylation, of the IGF1 gene
promoter at either CpG site were found between sites or
treatment arms (CpG 1077 Guatemala: control 5.6% ± 1.0%
compared with preconceptional SQLNS 4.2% ± 1.3%;
Pakistan: control 4.2% ± 0.9% compared with preconceptional SQLNS 4.7% ± 0.8%; CpG 1132 Guatemala:
control 7.1% ± 0.9% compared with preconceptional SQLNS
6
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7.0% ± 1.6%; Pakistan: control 6.3% ± 1.7% compared
with preconceptional SQLNS 5.0% ± 0.8%). Importantly, a
significant negative correlation was observed between DNA
methylation at the CpG 1077 region of the IGF1 gene promoter
and the mRNA expression of IGF1 by the placenta for Pakistani
participants only. No association existed between methylation
at the CpG 1132 region and placental IGF1 mRNA expression
(Figure 3A, B). Birth length z-score was not associated with
DNA methylation of the IGF1 gene promoter at either of
the CpG 1077 or CpG 1132 sites in placentas from Pakistani
participants (Figure 3C, D).
In placentas from Guatemalan participants, we found no
significant relation of DNA methylation of the IGF1 gene
promoter at the CpG 1077 or CpG 1132 sites with placental
mRNA expression of IGF1 (Figure 3E, F). On the other hand,
we found a strong negative correlation (P = 0.0001) between
DNA methylation of the CpG 1132 region of the IGF1 gene
promoter and birth length z-score (Figure 3G) and birth weight
z-score (Supplemental Figure 4). Interestingly, in placentas from
Guatemalan participants DNA methylation of the IGF1 gene
promoter at CpG 1077 was not associated with birth length
(Figure 3H).

Effect of preconceptional SQLNS on circulating
maternal serum concentrations of IGFBP-3, IGFBP-4,
and IGFBP-5 and its association with fetal growth
Preconceptional SQLNS did not affect the maternal serum
concentration of IGFBP-3 in either Guatemalan or Pakistani
participants, and the IGFBP-3:IGF-1 ratio was not correlated
with birth length or birth weight z-score (Figure 4). In
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FIGURE 3 Associations between placental IGF1 gene promoter DNA methylation, placental IGF1 mRNA expression, and birth length z-score
in Pakistan (A–D) and Guatemala (E–H). Pearson’s correlation of placental DNA methylation of IGF1 gene promoter at the CpG 1132 site with
(A, E, n = 24) relative placental mRNA expression of IGF1 and (C, n = 19; G, n = 22) birth length z-score. Pearson’s correlation of placental
DNA methylation of IGF1 gene promoter at the CpG 1077 site with (B, F, n = 24) relative placental mRNA expression of IGF1 and (D, n = 20; H,
n = 22) birth length z-score. AU, arbitrary units; IGF-1, insulin-like growth factor-1.

contrast, in Guatemalan participants preconceptional SQLNS
significantly increased maternal serum concentration of IGFBP4 (P = 0.01) and this was borderline significantly increased
in Pakistani participants (P = 0.08). However, there was no
correlation between maternal serum IGFBP-4 and birth length
or birth weight z- scores in either cohort (Figure 5). IGFBP-5 was
not affected by SQLNS and was not associated with fetal growth
parameters in either population (Figure 6). In Guatemalan
participants only, maternal serum IGFBP-5 was positively
correlated with maternal serum zinc (P = 0.04, r = 0.40) and
there was a borderline significant positive correlation between
IGFBP-5 and maternal serum IGF-1 concentrations (P = 0.07,
r = 0.34).
Effect of preconceptional SQLNS on placental protein
expression of PAPP-A and maternal serum zinc and its
association with placental area and fetal growth
PAPP-A modulates IGF-1 bioavailability and is released by the
placenta, therefore we examined placental protein expression
of PAPP-A. In both Pakistani and Guatemalan participants,
preconceptional SQLNS supplementation resulted in a pronounced 50-fold increase in placental protein expression of
PAPP-A (Figure 7A, E). Overall, a positive correlation was
found between placental protein expression of PAPP-A and
maternal serum concentration of IGF-1 in the preconceptional
SQLNS group (P = 0.01, r = 0.47) independent of the study
site. Placental expression of PAPP-A was not associated with

changes in maternal serum IGFBP-3 (Guatemala: P = 0.33,
r = 0.10; Pakistan: P = 0.22, r = −0.18), positively correlated
with maternal serum IGFBP-4 in Guatemalan participants
(P = 0.02, r = 0.46) but not in Pakistani participants (P = 0.10,
r = 0.28), and positively correlated with maternal serum IGFBP5 in Guatemalan participants (P = 0.05, r = 0.36) but not
in Pakistani participants (P = 0.16, r = −0.23). We found
no associations with birth length and birth weight z-scores
or placental area in any of the study sites (Figure 7B–D,
F–H).
Because PAPP-A is a proteolytic enzyme dependent on zinc
for its activity, circulating maternal serum zinc concentrations
and placental zinc transporter SLC39A10 were determined. In
Pakistani participants we found that preconceptional SQLNS
increased maternal serum zinc concentrations (Figure 8) and
maternal serum zinc was borderline significantly positively
correlated (P = 0.07, r = 0.35) with birth weight z-score.
In Guatemalan participants, we found no differences between
treatment arms in maternal serum zinc concentrations and
no associations with birth length or birth weight z-scores.
Placental zinc transporter SLC39A10 protein expression was
not affected by SQLNS in either population (Supplemental
Figure 5A, E) and was not associated with fetal growth
parameters or with placental PAPP-A protein expression in any
study site (Supplemental Figure 5B–H). Only in Guatemalan
participants receiving SQLNS, we found a positive association
between placental zinc transporter and placental PAPP-A
Maternal supplementation and placental function
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FIGURE 4 Effect of preconceptional SQLNS on maternal serum concentration of IGFBP-3 and its association with fetal growth in Pakistan
(A–C) and Guatemala (D–F). The histogram shows maternal serum concentrations of IGFBP-3 by treatment arm (control, arm 3; SQLNS, arm 1)
and site. Data are presented as mean ± SEM (A, n = 10; D, n = 12). Pearson’s correlation between maternal concentration of IGFBP-3 and (B,
n = 19; E; n = 18) birth length z-score and (C, n = 19; F, n = 17) birth weight z-score by site. IGFBP-3, insulin-like growth factor binding protein-3;
IGF-1, insulin-like growth factor-1; SQLNS, small-quantity lipid-based nutrient supplementation.

protein expression (SQLNS: P = 0.003, r = 0.72; Control:
P = 0.39, r = 0.08).
Effect of preconceptional SQLNS on maternal serum
PAPP-A and PAPP-A2 and its association with fetal
growth
Preconceptional SQLNS did not change circulating maternal
concentrations of PAPP-A at 34 weeks of gestation in Pakistani
(Control: 31.6 ± 4.05 mIU/mL; SQLNS: 42.9 ± 7.09
mIU/mL) or Guatemalan participants (Control: 30.5 ± 4.68
mIU/mL; SQLNS: 26.8 ± 5.90 mIU/mL). Maternal serum
concentrations of PAPP-A were not associated with birth
length or birth weight z-score, maternal serum IGF-1, zinc,
or IGFBP-3, -4, and -5 in either study site (Table 2). In
Pakistani participants preconceptional SQLNS did not change
maternal concentrations of PAPP-A2 at 34 weeks of gestation
(Control: 62.3 ± 9.32 ng/mL; SQLNS: 63.8 ± 17.3 ng/mL). In
contrast, Guatemalan participants had significantly decreased
serum concentrations of PAPP-A2 (Control: 78.7 ± 21.9 ng/mL;
SQLNS: 49.1 ± 10.9 ng/mL; P = 0.05). In addition, in
Guatemalan participants maternal serum concentration of
PAPP-A2 was positively associated with birth length z-score
(P = 0.01, r = 0.54) and with birth weight z-score (P = 0.01,
r = 0.52). No associations were found with maternal serum
IGF-1, maternal serum zinc, or IGFBP-3, -4, and -5 in either
study site (Table 2).
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Discussion
In the present study, we demonstrated differential effects
of a preconceptional maternal SQLNS on placental growth,
function, and IGF-1 signaling in women living in low-resource
countries where stunting is prevalent. In Pakistani participants,
preconceptional SQLNS resulted in decreased placental AMPK
activity, indicating improved cellular energy amounts and
activation of placental nutrient sensing through the mTOR
pathway. In Pakistani participants, maternal serum IGF-1
concentration and placental IGF-1 mRNA expression were
correlated with fetal growth. In contrast, in Guatemalan
participants who entered pregnancy with a greater BMI,
preconceptional SQLNS did not modify placental AMPK or
mTOR signaling. Placental expression and maternal serum
IGF-1 concentration showed no correlation with fetal growth
parameters. We propose that SQLNS effects on placental
function and fetal growth in these low-income populations
are dependent, in part, on maternal nutritional status defined
by BMI. These distinct placental responses to SQLNS may
help to explain the primary outcome in the WF trial, where
preconceptional SQLNS in Pakistani participants resulted in
significant increases in birth length z-score as compared with
the control arm, with the mean effect size being substantial
and similar to other reported maternal nutrition interventions.
In Guatemalan participants the mean length-for-age z-score
between the preconceptional SQLNS and control groups was
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FIGURE 5 Effect of preconceptional SQLNS on maternal serum IGFBP-4 and its association with fetal growth in Pakistan (A–C) and Guatemala
(D–F). The histogram shows maternal serum concentration of IGFBP-4 by treatment arm (control, arm 3; SQLNS, arm 1) and site. Data are
presented as mean ± SEM (A, n = 11; D, n = 10). ∗ Different from control, P < 0.05 (Student’s unpaired t test). Pearson’s correlation between
maternal serum concentration of IGFBP-4 and (B, n = 18; E, n = 17) birth length z-score and (C, n = 19; F, n = 17) birth weight z-score by site.
IGFBP-4, insulin-like growth factor binding protein-4; SQLNS, small-quantity lipid-based nutrient supplementation.

not different and preconceptional SQLNS did not improve
linear growth.
Fetal growth is determined by a wide variety of factors including genetic influences, maternal nutritional status
and metabolism, weight gain, and placental growth and
nutrient transport capacity. Many LMICs are undergoing
the so-called “double burden” of malnutrition, which is
characterized by growth stunting or wasting that coexists
with overweight/obesity (33, 34). Because overweight and
obesity are increasing rapidly in LMICs (35), this coexistence
exacerbates the risk of metabolic disease later in life and the
transgenerational transmission of metabolic diseases (3, 36).
Maternal undernutrition is strongly associated with intrauterine
growth restriction (37), downregulation of placental mTOR,
and a range of placental nutrient transport systems (38–
40). In the present study, half of Guatemalan participants
entered pregnancy being overweight, whereas Pakistani participants were of normal to low weight. This difference in
maternal nutrient reserves as measured by BMI resulted in
distinct nutritional interventions according to the WF protocol.
Guatemalan participants were primarily supplemented only
with the SQLNS. In contrast, the majority of the Pakistani
participants received both the SQLNS and a protein-energy
supplement due to either low preconceptional BMI or lack of
adequate weight gain during pregnancy. This difference in the
nutritional intervention protocol may contribute to the distinct

placental responses to the maternal supplementation observed
in the 2 subcohorts.
Placental size and functional capacity are key determinants
of fetal growth and can be modified by aspects of maternal
nutritional status, such as BMI. Placental nutrient transporters
are regulated in response to maternal nutrient supply (41).
Nutrient transfer to the fetus is dependent on the transport
surface area and placental size is a surrogate measure of surface
area (11). Placental weight as a measure of placental size is
correlated closely with birth weight (42). In our study placental
weight was not measured; however, Guatemalan participants
had greater placental area than Pakistani participants. This is
in agreement with studies showing that higher maternal BMI is
associated with increased placental size (43, 44). Interestingly,
a significant increase in placental area was found in Pakistani
participants who received SQLNS as compared with control
participants, and when SQLNS and control groups were pooled,
a positive correlation between placental area and birth length
and birth weight z-scores was found. Prior studies have shown
that placental weight and the ratio of placental weight to birth
weight are predictive of maternal disease, perinatal morbidity
and mortality, as well as childhood growth and development
(45, 46). Thus, placental growth and function are key mediators
of adequate intrauterine fetal growth and lifelong health. Our
study demonstrates the interaction between maternal nutrient
status, nutrient supplementation, and placental size in women
Maternal supplementation and placental function
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FIGURE 6 Effect of preconceptional SQLNS on maternal serum IGFBP-5 and its association with fetal growth in Pakistan (A–C) and Guatemala
(D–F). The histogram shows maternal serum concentration of IGFBP-5 by treatment arm (control, arm 3; SQLNS, arm 1) and site. Data are
presented as mean ± SEM (A, n = 11; D, n = 10). Pearson’s correlation between maternal serum concentration of IGFBP-5 and (B, n = 18; E,
n = 17) birth length z-score and (C, n = 19; F, n = 18) birth weight z-score by site. IGFBP-5, insulin-like growth factor binding protein-5; SQLNS,
small-quantity lipid-based nutrient supplementation.

with low nutrient reserves who are supplemented during
pregnancy.
Nutrient-sensing pathway intrinsic to the placenta
Placental nutrient transporters are regulated in response to
maternal nutrient supply (47). Nutrient-sensing pathways in the
placenta include mTOR signaling, which has been shown to
regulate placental nutrient transporter expression and activity
(13, 48). Previous studies in animal models and human
pregnancies have demonstrated that mTOR regulates placental
nutrient transporters in response to a wide variety of signals,
including growth factors such as IGF-1. Notably, placental
mTOR activity is decreased in placentas of intrauterine-growthrestricted human infants (49). Inhibition of mTOR markedly
decreases the activity of key placental amino acid transporters
in cultured primary human trophoblast cells (13, 48). Therefore,
dysregulation of placental mTOR plays an important role in
abnormal fetal growth by modulating the delivery of nutrients
to the fetus (48).
Two distinct patterns of placental mTOR activity were
observed in women who received preconceptional SQLNS. In
underweight Pakistani participants, preconceptional SQLNS
combined with protein-energy supplementation stimulated
placental mTOR signaling. In Guatemalan participants with
greater caloric reserves and high rates of maternal stunting,
preconceptional SQLNS did not affect placental mTOR signaling. We propose that these distinct responses are due, in
10
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part, to differences in maternal nutritional status, and possibly
modulated by the differences in the interventional protocol in
these 2 sites. Our data suggest that, in Pakistani participants,
preconceptional SQLNS together with a protein-energy supplement activated placental mTOR and IGF-1 signaling, likely
increasing placental growth and nutrient transfer to improve
fetal growth. Given that mTOR is particularly responsive
to amino acid availability, it cannot be excluded that the
additional protein-energy supplement provided to the Pakistani
participants contributed to placental mTOR activation and
increased fetal growth. In Guatemalan participants, SQLNS did
not activate placental mTOR or IGF-1 signaling and did not
promote fetal growth.
IGF-1 axis and regulation of fetal growth
Maternal hormones such as insulin, leptin, adiponectin, and
IGF-1 are factors that regulate placental transport through
mTOR signaling. IGF-1 is known to modulate placental
transport of nutrients and provides a link between maternal
nutritional status and placental nutrient transport (50). Contrary to our hypothesis, maternal preconceptional SQLNS did
not affect the circulating maternal serum concentration of IGF1 nor DNA methylation of the placental IGF1 gene promoter
in either study site. We observed that maternal serum IGF-1 and
placental mRNA expression of IGF1 were positively correlated
with birth size parameters in Pakistani participants. In contrast,
in Guatemalan participants we found a positive correlation
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FIGURE 7 Effect of preconceptional SQLNS on placental protein expression of PAPP-A and its association with fetal growth in Pakistan (A–D)
and Guatemala (E–H). The histogram shows relative placental protein expression of PAPP-A by treatment arm (control, arm 3; SQLNS, arm 1) and
site (A, E). Data are presented as mean ± SEM, n = 12. Representative individual Protein Simple Western Blot capillaries are shown for PAPP-A
and vinculin as loading control. ∗∗ Different from control, P < 0.005 (Student’s unpaired t test). Pearson’s correlation between relative placental
protein expression of PAPP-A and (B, n = 19; F, n = 22) birth length z-score, (C, n = 19; G, n = 22) birth weight z-score, and (D, n = 17; H, n = 19)
placental area. AU, arbitrary units; PAPP-A, pregnancy associated plasma protein-A; SQLNS, small-quantity lipid-based nutrient supplementation.

of placental protein expression of IGF-1R with fetal growth
but not with maternal serum IGF-1 or placental expression.
These data suggest important differences in the regulation of
intrauterine growth in Guatemalan and Pakistani women, a
concept supported by the distinct relations between placental
IGF1 gene promoter DNA methylation and fetal growth in
the 2 cohorts. Specifically, in Guatemala, but not in Pakistan,
we found a striking negative relation between placental DNA
methylation of the IGF1 gene promoter and fetal growth.
Previous studies have shown that, in small-for-gestational-age
infants, placental IGF1 mRNA expression was decreased and
corresponded to hypermethylation of the IGF1 gene promoter,
indicating that epigenetic modification of the placental IGF1
gene may regulate fetal growth (24). In the placentas of
Guatemalan participants, DNA methylation of the IGF1 gene
promoter at the 2 studied CpG sites was not associated with
changes in placental IGF1 mRNA expression, suggesting the
impact of this change in methylation on fetal growth may not be
due to direct changes in IGF-1 concentration but may operate
through an alternative, as yet unidentified, pathway.
IGF activity is regulated through interaction with IGFBPs
and proteases such as PAPP-A and PAPP-A2 that cleave IGFBPs,
providing an additional layer of complexity for modulating the
bioavailability of IGFs. IGFBP-4 modulates IGF bioavailability
and is a primary substrate for PAPP-A. Cleavage of the binding
protein causes the release of IGF-1, allowing it to interact with
receptors. In human pregnancy, PAPP-A is synthesized by the
syncytiotrophoblast and circulating concentrations of PAPP-A
increase across gestation as a reflection of increasing placental
size (51). Reduced maternal concentrations of PAPP-A have
been associated with pre-eclampsia and intrauterine growth
retardation (52). Higher concentrations in the first trimester of
pregnancy have been associated with large-for-gestational-age

infants (20). Recently, positive associations of umbilical cord
blood total IGFBP-4 and IGFBP-5 with birth length and birth
weight z-scores have been demonstrated (53). We found an
increase in maternal serum IGFBP-4 and in placental expression
of PAPP-A with preconceptional SQLNS in both populations.
In contrast, we did not find associations of maternal serum
IGFBP-3, IGFBP-4, IGFBP-5, and PAPP-A with fetal growth
parameters in either studied population. PAPP-A and PAPPA2 in umbilical cord blood have been negatively associated
with birth weight and birth length z-scores (53). In our study
populations, maternal serum PAPP-A was not associated with
fetal growth parameters. Only Guatemalan participants were
found to have a positive association between PAPP-A2 and birth
length and birth weight z-scores.
Zinc is an essential micronutrient during pregnancy and
throughout life. Maternal zinc deficiency impairs fetal embryogenesis, growth, and placental development. However, the exact
mechanisms are unclear. Our data suggest that in Pakistani
participants serum zinc concentrations were improved with
preconceptional SQLNS, which may contribute to the observed
increase in birth length z-score reported in the larger WF
trial (54). Zinc is an important cofactor for PAPP-A activity.
Improved maternal zinc concentration in Pakistani participants
receiving SQLNS may in part explain the response to IGF1 signaling. The interaction of zinc with IGFBPs to regulate
IGF signaling has been described in myoblasts by lowering
the affinity of soluble IGFBP-5 for IGF-1 and thus increasing
the availability of IGF-1 (55). In our study, only Guatemalan
participants had positive associations of maternal serum IGFBP5 with maternal serum IGF-1 and zinc. Whether increased zinc
availability impinges on signaling pathways known to regulate
placental function, such as mTOR and IGF-1 signaling, remains
to be established.
Maternal supplementation and placental function
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FIGURE 8 Effect of preconceptional SQLNS on maternal serum concentration of zinc and its association with fetal growth in Pakistan (A–D)
and Guatemala (E–H). The histogram shows maternal serum zinc concentration by treatment arm (control, arm 3; SQLNS, arm 1) and site.
Data are presented as mean ± SEM (A, n = 12; E, n = 10). ∗ Different from control, ∗ P < 0.05 (Student’s unpaired t test). Pearson’s correlation
between maternal zinc serum concentration and (B, n = 19; F, n = 17) birth length z-score, (C, n = 19; G, n = 17) birth weight z-score, and (D,
n = 20; H, n = 19) relative placental protein expression of PAPP-A. AU, arbitrary units; PAPP-A, pregnancy associated plasma protein-A; SQLNS,
small-quantity lipid-based nutrient supplementation.

TABLE 2 Associations of maternal serum PAPP-A and PAPP-A2 with fetal growth parameters and hormones, by study site1
Birth length
z-score

1
∗

0.29
0.15
− 0.01
0.54∗

Maternal serum
IGF-1

0.15
− 0.04

− 0.02
− 0.08

0.32
0.18

− 0.22
− 0.25

0.14
− 0.17

0.10
0.52∗

Maternal serum
zinc

Placental
area

IGFBP-3

IGFBP-4

IGFBP-5

0.31
− 0.22

− 0.11
0.08

0.01
− 0.02

− 0.14
0.08

0.55∗
− 0.07

0.31
− 0.24

0.34
− 0.11

− 0.07
− 0.36

Values are Pearson’s correlation coefficients. IGFBP, insulin-like growth factor binding protein; IGF-1, insulin-like growth factor-1; PAPP, pregnancy associated plasma protein.
P < 0.05.

Zinc influx (Slc39/ZIP, members 1–14) proteins transport
zinc into the cell when zinc in the cytosol is low or depleted.
Zinc transporters have been implicated in the activation of
key cell signaling molecules associated with insulin signaling.
In our study, placental zinc transporter SLC39A10 protein
expression was not affected by SQLNS in either study site but
was positively associated with placental PAPP-A in Guatemalan
women receiving SQLNS. The role of the placenta in regulating
micronutrient transport in response to maternal nutrient status
is still under investigation. It is known that the placenta
upregulates gene expression of zinc uptake transporters in order
to meet fetal demands under low maternal zinc concentrations
(56).
Functions of PAPP-A unrelated to IGF signaling are also
possible and may rely on the cleavage of substrates other than
IGFBPs, or a function independent of its proteolytic activity
associated with early development (57). Although PAPP-A has
been associated with fat deposition and body composition (58,
59), we did not observe an association between placental PAPPA and weight gain at 34 weeks of gestation in this subset of

participants at either study site (Guatemala: P = 0.45, r = 0.02;
Pakistan: P = 0.45, r = 0.02).
Strengths and limitations
A strength of this study is the opportunity to evaluate the
effect of a preconceptional nutritional intervention on placental
function and fetal growth in 2 low-resource populations
with different maternal anthropometric measures related to
nutritional status. We acknowledge that the small sample
size limits our statistical power in some of the observed
associations and does not necessarily represent the cohorts
as a whole. Sex differences in fetal growth trajectories and
sex-specific risk factors have been recognized (60) but we
were unable to specifically study the effect of fetal sex on
our outcomes; a balance of female and male newborns was
included in the analysis to ensure fetal sex dimorphism was not
contributing to the current findings. We also acknowledge the
genetic background of the 2 populations might have influenced
the response. The WF trial will more broadly evaluate the
epigenome of mother, fetus, and offspring in future studies.

FIGURE 9 Integrative model of examined variables in the maternal circulation and in the placenta. Representation of examined variables in
the maternal circulation (left) associated with the regulation of the IGF-1 pathway: IGF-1; IGFBP-3, IGFBP-4, and IGFBP-5; PAPP-A and PAPP-A2;
and zinc. Description of examined variables in the placenta (61) associated with the IGF-1/mechanistic target of rapamycin pathway and fetal
growth: mRNA expression of IGF1; IGF-1R; AMPKA; rpS6; 4E-BP1; DNA methylation of IGF1 promoter at the CpG 1132 and 1077 sites; and
SLC39A10. Study main findings are highlighted by circles. AMPKA, AMP-activated protein kinase α; Akt, protein kinase B; eIF4E, eukaryotic
translation initiation factor 4E; IGFBP, insulin-like growth factor binding protein; IGF-1, insulin-like growth factor-1; IGF-1R, insulin-like growth
factor 1 receptor; mTORC1, mechanistic target of rapamycin complex 1; PAPP, pregnancy-associated plasma protein; rpS6, ribosomal protein
S6; SLC39A10, zinc influx SLC39A transporter; S6K1, ribosomal protein S6 kinase β-1; 4E-BP1, eukaryotic translation initiation factor binding
protein-1.
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